Skip to content
Home
Technology
Pipeline
Our Companies
Leadership
Leadership Voices
News & Events
Join Us
Contact
News & Events
Our latest news
[image placeholder – do not delete]
Select Company
All
Altavant
Enzyvant
Myovant
Spirovant
Sumitovant
Urovant
December 27, 2019
Sumitomo Dainippon Pharma Completes the Formation of the Strategic Alliance
October 16, 2019
Enzyvant Appoints Jeb Ledell as Chief Operating Officer
June 05, 2019
Enzyvant Announces FDA Acceptance of Biologics License Application (BLA) and Priority Review Status for RVT-802, a Novel Investigational Tissue-Based Regenerative Therapy for Pediatric Congenital Athymia
March 21, 2019
Enzyvant’s Investigational Farber Disease Enzyme Replacement Therapy, RVT-801, Receives FDA Fast Track and Rare Pediatric Disease Designations
February 21, 2019
Enzyvant Appoints Industry Veteran Rachelle Jacques as Chief Executive Officer
February 04, 2019
Enzyvant to Highlight Investigational RVT-801 Program and Farber Disease Natural History Study at Upcoming WORLDSymposiumâ„¢